NCT03736720View on ClinicalTrials.gov

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

October 18, 2022

Study Completion Date

August 26, 2024

Conditions
Locally Advanced Digestive System Neuroendocrine CarcinomaLocally Advanced Pancreatic Neuroendocrine CarcinomaMetastatic Digestive System Neuroendocrine CarcinomaMetastatic Pancreatic Neuroendocrine CarcinomaRefractory Digestive System Neuroendocrine CarcinomaRefractory Pancreatic Neuroendocrine CarcinomaUnresectable Digestive System Neuroendocrine CarcinomaUnresectable Pancreatic Neuroendocrine Carcinoma
Interventions
DRUG

Fluorouracil

Given IV

DRUG

Leucovorin

Given IV

DRUG

Liposomal Irinotecan

Given IV

PROCEDURE

Quality-of-Life Assessment

Correlative studies

Trial Locations (2)

11794

Stony Brook Cancer Center, Stony Brook

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER